HemOnc today | JANUARY 10, 2016 | Healio.com/HemOnc 5 Lung Cancer Drugs in the Pipeline HEMONC TODAY presents this guide to drugs in phase 2 or phase 3 development for lung cancer-related indications. Clinicians can use this chart as a quick reference to learn about the status of those drugs that may be clinically significant to their practice. Generic name (Brand name, Manufacturer) Indication(s) Development status abemaciclib (Eli Lilly) non–small cell lung cancer phase 3 ABP 215 (Allergan/Amgen) non–small cell lung cancer (advanced disease) phase 3 ACP-196 (Acerta Pharma) non–small cell lung cancer (advanced disease) phase 2 ado-trastuzumab emtansine (Kadcyla, Genentech) non–small cell lung cancer (HER-2–positive disease) phase 2 afatinib (Gilotrif, Boehringer Ingelheim) lung cancer (squamous cell carcinoma) phase 3 aldoxorubicin (CytRx) small cell lung cancer phase 2 alectinib (Alecensa, Genentech) non–small cell lung cancer (second-line treatment of ALK-positive disease) phase 2 non–small cell lung cancer (first-line treatment of ALK-positive disease); phase 3 alisertib (Takeda) malignant mesothelioma, small cell lung cancer phase 2 avelumab (EMD Serono/Pfizer) non–small cell lung cancer phase 3 AZD9291 (AstraZeneca) non–small cell lung cancer (first-line treatment of advancedEGFR -positive disease; phase 3 second-line treatment of advanced EGFR-positive, T790M-positive disease) bavituximab (Peregrine Pharmaceuticals) non–small cell lung cancer (previously treated advanced/metastatic disease) phase 3 belinostat (Beleodaq, Spectrum Pharmaceuticals) non–small cell lung cancer phase 2 bevacizumab (Avastin, Genentech) non–small cell lung cancer (adjuvant therapy) phase 3 BI 695502 (Boehringer Ingelheim) non–small cell lung cancer (nonsquamous histology) phase 3 BIND-014 (BIND Therapeutics) non–small cell lung cancer (KRAS-mutated disease; squamous histology disease) phase 2 brigatinib (ARIAD) non–small cell lung cancer (ALK-positive disease) phase 2 carfilzomib (Kyprolis, Onyx Pharmaceuticals) small cell lung cancer phase 2 CC-486 (Celgene) non–small cell lung cancer (advanced disease) phase 2 CD40LGVAX (Cellular Biomedicine) non–small cell lung cancer phase 2 ceritinib (Zykadia, Novartis) non–small cell lung cancer (first-line treatment of treatment-naive, phase 2 ALK-positive disease) crenolanib (AROG Pharmaceuticals) non–small cell lung cancer phase 2 custirsen (OncoGenex Pharmaceuticals) non–small cell lung cancer (advanced disease) phase 3 CX-01 (Cantex Pharmaceuticals) small cell lung cancer phase 2 dabrafenib (Tafinlar, Novartis) non–small cell lung cancer (combination therapy for BRAF V600-positive disease) phase 2 dacomitinib (Pfizer) non–small cell lung cancer (first-line treatment of EGFR-mutant disease) phase 3 denosumab (Xgeva, Amgen) non–small cell lung cancer (first-line treatment of metastatic disease) phase 2 DPV-001 (UbiVac) non–small cell lung cancer phase 2 durvalumab (MedImmune) non–small cell lung cancer (stage III disease; third-line treatment of phase 3 PD-L1–positive disease) EGF816 (Novartis) non–small cell lung cancer phase 2 emibetuzumab (Eli Lilly) non–small cell lung cancer phase 2 entinostat (Syndax Pharmaceuticals) non–small cell lung cancer phase 2 epacadostat (Incyte) non–small cell lung cancer phase 2 eribulin (Halaven, Eisai) non–small cell lung cancer phase 3 erlotinib (Tarceva, Genentech) non–small cell lung cancer (first-line treatment of metastatic, EGFR-positive disease) phase 3 everolimus (Afinitor, Novartis) neuroendocrine lung tumors phase 3 evofosfamide (TH-302; EMD Serono, Threshold Pharmaceuticals) non–small cell lung cancer phase 2 ficlatuzumab (AVEO Oncology) non–small cell lung cancer (advanced disease) phase 2 ganetespib (Synta Pharmaceuticals) non–small cell lung cancer phase 3 GI-4000 (GlobeImmune) non–small cell lung cancer phase 2 Imprime PGG (Biothera) non–small cell lung cancer (first-line treatment of metastatic disease) phase 2 INC280 (Novartis) non–small cell lung cancer phase 2 INCB39110 (Incyte) non–small cell lung cancer phase 2 ipilimumab (Yervoy, Bristol-Myers Squibb) non–small cell lung cancer (first-line treatment, squamous histology) phase 3 lenvatinib (Lenvima, Eisai) non–small cell lung cancer (third-line treatment; RET translocations) phase 2 lucitanib (Clovis Oncology) non–small cell lung cancer (squamous histology) phase 2 LY2510924 (Eli Lilly) small cell lung cancer phase 2 LY3023414 (Eli Lilly) non–small cell lung cancer phase 2 ME-344 (MEI Pharma) small cell lung cancer phase 2 6 HemOnc today | JANUARY 10, 2016 | Healio.com/HemOnc Lung Cancer Drugs in the Pipeline Generic name (Brand name, Manufacturer) Indication(s) Development status MGCD265 (Mirati Therapeutics) non–small cell lung cancer (late-stage disease) phase 2 MORAb-003 (Eisai) non–small cell lung cancer phase 2 MORAb-009 (Eisai) mesothelioma phase 2 napabucasin (Boston Biomedical) malignant pleural mesothelioma phase 2 NC-6004 (NanoCarrier) non–small cell lung cancer phase 2 NGR-TNF (MolMed) mesothelioma (late-stage disease) phase 3 NK012 (Nippon Kayaku) small cell lung cancer phase 2 nintedanib (Vargatef, Boehringer Ingelheim) mesothelioma phase 2 non–small cell lung cancer (combination therapy) phase 3 onalespib (Astex Pharmaceuticals) non–small cell lung cancer phase 2 patritumab (Daiichi Sankyo) non–small cell lung cancer phase 2 PB272 (Puma Biotechnology) non–small cell lung cancer (HER-2–positive disease) phase 2 PEGPH20 (Halozyme Therapeutics) non–small cell lung cancer phase 2 pelareorep (Reolysin, Oncolytics Biotech) non–small cell lung cancer, squamous cell carcinoma of the lung phase 2 pembrolizumab (Keytruda, Merck) non–small cell lung cancer phase 3 PF-06439535 (Pfizer) non–small cell lung cancer phase 3 pictilisib (Genentech/Roche) non–small cell lung cancer (metastatic disease) phase 2 plinabulin (BeyondSpring Pharmaceuticals) non–small cell lung cancer (second-line treatment) phase 2 PT 107 (Pique Therapeutics) non–small cell lung cancer phase 2 ramucirumab (Cyramza, Eli Lilly) non–small cell lung cancer phase 3 RG7446 (Genentech/Roche) non–small cell lung cancer (third-line treatment) phase 2 non–small cell lung cancer (second-line combination treatment; first-line treatment) phase 3 rociletinib (Clovis Oncology) non–small cell lung cancer (first- or second-line treatment ofEGFR -mutated disease) phase 2 non–small cell lung cancer (third-line or later treatment for EGFR-mutated disease) phase 3 roniciclib (Bayer HealthCare) small cell lung cancer phase 2 RRx-001 (EpicentRx) non–small cell lung cancer, small cell lung cancer phase 2 ruxolitinib (Jakafi, Incyte) non–small cell lung cancer phase 2 sapacitabine (Cyclacel Pharmaceuticals) non–small cell lung cancer phase 2 SAR125844 (Sanofi) non–small cell lung cancer phase 2 SC16LD6.5 (Stemcentrx) small cell lung cancer (recurrent disease) phase 2 selumetinib (AstraZeneca) non–small cell lung cancer (second-line treatment of KRAS wild-type disease) phase 2 non–small cell lung cancer (second-line treatment of KRAS-mutant disease) phase 3 seribantumab (MM-121, Merrimack Pharmaceuticals) non–small cell lung cancer phase 2 SPI-1620 (Spectrum Pharmaceuticals) non–small cell lung cancer phase 2 tarextumab (OncoMed Pharmaceuticals) small cell lung cancer (first-line treatment of extensive-stage disease) phase 2 tepotinib (EMD Serono) non–small cell lung cancer phase 2 tergenpumatucel-L (NewLink Genetics) non–small cell lung cancer (advanced or metastatic disease) phase 3 tesevatinib (KD019, Kadmon Pharmaceuticals) non–small cell lung cancer phase 2 TG4010 (Transgene) non–small cell lung cancer (advanced disease) phase 3 TH-4000 (Threshold Pharmaceuticals) non–small cell lung cancer (T790M-negative disease) phase 2 trametinib (Mekinist, Novartis) non–small cell lung cancer (combination therapy for BRAF V600-positive disease) phase 2 trebananib (Amgen) non–small cell lung cancer phase 2 tremelimumab (MedImmune) mesothelioma phase 3 TSR-011 (TESARO) non–small cell lung cancer phase 2 TUSC2 (Genprex) non–small cell lung cancer phase 2 veliparib (AbbVie) non–small cell lung cancer phase 3 viagenpumatucel-L (Heat Biologics) non–small cell lung cancer phase 2 vintafolide (Endocyte) non–small cell lung cancer phase 2 VS-6063 (Verastem) mesothelioma, non–small cell lung cancer (KRAS-mutant disease) phase 2 X-396 (Xcovery) non–small cell lung cancer (ALK-positive disease) phase 2 Information in this chart was compiled from the Pharmaceutical Research and Manufacturers of America, NIH (www.clinicaltrials.gov), corporate websites and the databases of HEMONC TODAY. The publisher or editors do not assume responsibility for any errors or omissions..